Locally advanced cervical cancer
Conditions
Interventions
experimental group:1. Tislelizumab 200mg, IV, 1 day before radiotherapy, q3w Until the disease progresses / or lasts for 1 year
2. concurrent chemoradiotherapy.
Sponsors
Suzhou Municipal Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with stage II a2 - IV a (2018 FIGO stage) locally advanced cervical cancer; 2. Patients with ECoG grade 0-1; life expectancy > 6 months; 3. Patients aged 18-70 years; 4. Patients who did not use chemotherapy before being selected; 5. Patients without radiotherapy history; 6. Patients without surgery; 7. Patients without serious allergic history; 8. Hemoglobin >= 100 g / L, WBC >= Three point five x 10 ^ 9 / L, neutrophils >= One point five x 10 ^ 9 / L, platelet >= 100 x 10 ^ 9 / L; Cr <= One point five Times normal upper limit, TB <= two point five Times normal upper limit, AST and alt <= Two point five Times normal upper limit, AKP <= Two point five Times of normal upper limit; 9. Patients willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with history of malignant tumor in other parts; 2. Pregnant or lactating patients; 3. Patients with a history of immunodeficiency, or other acquired or congenital immunodeficiency diseases, or organ transplantation; 4. Patients with previous thyroid dysfunction, and in the case of drug treatment, thyroid function still can not be maintained in the normal range; 5. Patients in the active stage of infectious diseases; 6. Patients participating in other clinical trials at present or within four weeks before selection; 7. Patients treated with other anti-cancer drugs (including anti-cancer traditional Chinese Medicine) at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year LRFFS%;3-year PFS%;LRC; | — |
Countries
China
Contacts
Public ContactZhou Jundong
Suzhou Municipal Hospital
Outcome results
None listed